These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23806498)

  • 21. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
    Climent MA; Piulats JM; Sánchez-Hernández A; Arranz JÁ; Cassinello J; García-Donas J; González del Alba A; León-Mateos L; Mellado B; Méndez-Vidal MJ; Pérez-Valderrama B;
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):341-52. PubMed ID: 22285697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maximal androgen ablation: a review.
    Miles BJ; Babiarz J
    Henry Ford Hosp Med J; 1992; 40(1-2):114-7. PubMed ID: 1428961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine prevention and treatment of prostate cancer.
    Tammela TL
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):59-67. PubMed ID: 22465099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States.
    Cetin K; Li S; Blaes AH; Stryker S; Liede A; Arneson TJ
    Urology; 2013 Jun; 81(6):1184-9. PubMed ID: 23601449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current treatment of advanced prostate cancer.
    Ismail M; Gomella LG
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hormone therapy in advanced and generalized carcinoma of the prostate].
    Vachalovský V; Dvorácek J; Voboril V
    Cas Lek Cesk; 1998 Aug; 137(17):532-6. PubMed ID: 9787507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies.
    Limonta P; Manea M
    Cancer Treat Rev; 2013 Oct; 39(6):647-63. PubMed ID: 23290320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controversies surrounding androgen deprivation for prostate cancer.
    Patterson SG; Balducci L; Pow-Sang JM
    Cancer Control; 2002; 9(4):315-25. PubMed ID: 12228757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.